TGFB2 and non-small cell lung carcinoma: While no literature currently exists describing the use of a recombinant antisense vaccine to protect against avian pathogens, antisense technology has proven successful in cancer research and against some viral pathogens, including the use of antisense TGF-β2 oligonucleotides in mice with brain tumors [55], TGF-β2 antisense tumor cell vaccine in humans with non-small cell lung cancer [56] and a sequence targeting the 5′ untranslated region of foot and mouth disease virus [57].